Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029856 | 0.85 | PLK1 (0.52) | GAAALDH1A1PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL9175687 | 0.83 | MAPT (0.50) | GAAALDH1A1RAB9ANPC1CYSLTR2 | |
| SCHEMBL6029416 | 0.83 | NR1I2 (0.48) | ALDH1A1CYSLTR2CYSLTR1KMT2APOLB | |
| SCHEMBL9254823 | 0.81 | CYSLTR2 (0.52) | GAAALDH1A1RAB9ANPC1PLK1 | |
| SCHEMBL10867011 | 0.77 | CYSLTR2 (0.53) | ALDH1A1RAB9ANPC1CYSLTR2CYSLTR1 | |
| SCHEMBL3656954 | 0.75 | POLB (0.45) | ALDH1A1RAB9ANPC1CYSLTR2CYSLTR1 | |
| SCHEMBL9570576 | 0.74 | BRD4 (0.65) | GAAALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL31467959 | 0.74 | GAA (0.80) | GAAALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL4629895 | 0.73 | KMT2A (0.54) | GAAALDH1A1NPC1CYSLTR2CYSLTR1 | |
| SCHEMBL9135676 | 0.73 | PLK1 (0.57) | RAB9ANPC1PLK1CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109376-B2 | Benzene and naphthylene derivatives and their use as UV screening agents | DSM IP ASSETS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20060153784-A1 | Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents | HUBER ULRICH | 2006-07-13 | — | — | US | disclosed |
| US-7019020-B2 | 2-benzoxazolyl benzene derivatives and their use as UV screening agents | DSM IP ASSETS B.V. (NL) | 2006-03-28 | — | — | US | disclosed |
| US-20040071640-A1 | Novel-2-benzoxazolyl benzene derivatives and their use as uv screening agents | DSM IP ASSETS B.V. (NL) | 2004-04-15 | — | — | US | disclosed |
| EP-1358167-A1 | NOVEL 2-BENZOXAZOLYL BENZENE DERIVATIVES AND THEIR USE AS UV SCREENING AGENTS | Roche Vitamins AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062771-A1 | NOVEL 2-BENZOXAZOLYL BENZENE DERIVATIVES AND THEIR USE AS UV SCREENING AGENTS | ROCHE VITAMINS AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071640-A1 | Novel-2-benzoxazolyl benzene derivatives and their use as uv screening agents | CBX8, XRCC5, CYP8B1 | GAA 4461/4885ALDH1A1 623/4885RAB9A 3805/4885 |
| US-20060153784-A1 | Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents | POLR1C, CBR3, CBR1 | GAA 4326/4885ALDH1A1 602/4885RAB9A 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.